| DC60657 |
Z6466608628
Featured
|
Z6466608628 is a CRBN molecular gluewith EC50 of 0.34 µM. Z6466608628 selectively recruits PPIL4, along with its binding partner DHX40. |
|
| DC60654 |
CDO1 degrader-1
Featured
|
CDO1 degrader-1 (compound 8) is a molecular glue degrader that targets cysteine dioxygenase (CDO1). |
|
| DC60658 |
ZZ1
Featured
|
ZZ1 is a YPEL5-GID/CTLH-dependent BRD4 degrader with CD50 of 502 nM. ZZ1 induces selective degradation of BET proteins (BRD3 and BRD4). |
|
| DC60659 |
ZZ2
Featured
|
ZZ2 is a YPEL5-GID/CTLH-dependent BRD4 degrader with CD50 of 169 nM. |
|
| DC60660 |
RGT-587
Featured
|
RGT-587 is a CDK inhibitor and selectively inhibits CDK4 but also has excellent brain penetration. |
|
| DC60661 |
RGT-419B
Featured
|
RGT-419B is a CDK inhibitor and not only actively inhibits CDK2, CDK4 and CDK6, but also demonstrates strong anti-proliferation activities. |
|
| A267 |
Sirukumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis. |
|
| A268 |
Elsilimomab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). |
|
| A269 |
Siltuximab Biosimilar (Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research. |
|
| A270 |
Olokizumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA). |
|
| A271 |
Clazakizumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. |
|
| A272 |
Chugai SK2 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A275 |
CSTRI patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A276 |
Medarex patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A277 |
MEDI 5117 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A278 |
Merck patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A129 |
Sarilumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis. |
|
| A279 |
Levilimab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid. |
|
| A280 |
APX-007 Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
|
|
| A281 |
Vobarilizumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. |
|
| A282 |
Sapelizumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
|
|
| A283 |
PF-06342674 Biosimilar(Anti-IL-7Ra / CD127 Reference Antibody）
Featured
|
|
|
| A284 |
Lusvertikimab Biosimilar（Anti-IL-7Ra / CD127 Reference Antibody）
Featured
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. |
|
| A285 |
Bapotulimab Biosimilar(Anti-ILDR2 Reference Antibody)
Featured
|
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects. |
|
| A286 |
Garetosmab Biosimilar(Anti-INHBA / Activin A Reference Antibody)
Featured
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. |
|
| A287 |
Oxford Brookes U. patent anti-Activin Beta-B Biosimilar(Anti-INHBB / Activin B Reference Antibody)
Featured
|
|
|
| A288 |
Scripps patent anti-CD11a Biosimilar(Anti-Integrin a11 / ITAG11 Reference Antibody)
Featured
|
|
|
| A289 |
Etrolizumab Biosimilar(Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody)
Featured
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD). |
|
| A290 |
Briakinumab Biosimilar(Anti-IL-12 (IL-12a & IL-12b) Reference Antibody)
Featured
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. |
|
| A291 |
Nipocalimab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6. |
|
